论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Luo J, Chen S, Min S, Peng L
Received 7 July 2018
Accepted for publication 17 October 2018
Published 10 December 2018 Volume 2018:14 Pages 2397—2406
DOI https://doi.org/10.2147/TCRM.S179420
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Amy Norman
Peer reviewer comments 2
Editor who approved publication: Professor Deyun Wang
Abstract: Postoperative
residual neuromuscular block is a serious threat which endangers the patient
safety. Neostigmine has been the most commonly used anticholinesterase for the
pharmacological reversal of neuromuscular blockade. Although newer agents have
been introduced recently, neostigmine has some irreplaceable advantages,
including broad-spectrum reversal of all nondepolarizing neuromuscular blocking
drugs, low cost, and availability of more related data for clinical practice to
refer to. Neostigmine is also noticed to have some drawbacks, such as the
inability to reverse profound and deep blockade, potential induction of muscle
weakness, cardiovascular adverse effects, and so on. Data on the usage of
neostigmine in the geriatric and the pediatric population are still
insufficient. Some discrepancies are observed in the results from previous
studies which need further investigation. However, recent studies offer some
renewed information. Regarding both efficacy and safety, the key for successful
reversal of neuromuscular blockade is to use neostigmine “appropriately,”
optimizing the dosage and timing of administration under close monitoring.
Keywords: postoperative
residual neuromuscular block, neuromuscular reversal, anticholinesterase,
postanesthesia care, postoperative complication
